EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments
March 05, 2025 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule – – Positive Phase 2 VERONA clinical trial of...
EyePoint Announces Participation at Upcoming Investor Conferences
March 04, 2025 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025
February 26, 2025 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference
February 25, 2025 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– Company presentation scheduled on Tuesday, March 4th at 9:10am ET – – EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal program in wet AMD and additional subgroup...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 17, 2025 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Feb. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints
February 05, 2025 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and...
EyePoint to Present at Guggenheim SMID Cap Biotech Conference
January 30, 2025 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 16, 2025 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Provides Company Update and Anticipated Development Milestones for 2025
January 13, 2025 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial tracking ahead of schedule – – Full data for Phase 2...
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors
January 08, 2025 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...